RT Journal Article
SR Electronic
T1 Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.19.20071472
DO 10.1101/2020.04.19.20071472
A1 Shi, Puyu
A1 Ren, Guoxia
A1 Yang, Jun
A1 Li, Zhiqiang
A1 Deng, Shujiao
A1 Li, Miao
A1 Wang, Shasha
A1 Xu, Xiaofeng
A1 Chen, Fuping
A1 Li, Yuanjun
A1 Li, Chunyan
A1 Yang, Xiaohua
A1 xie, Zhaofeng
A1 Wu, Zhengxia
A1 chen, Mingwei
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.19.20071472.abstract
AB Background The mortality of COVID-19 differs between countries and regions. By now, reports on COVID-19 are largely focused on first-generation cases. This study aimed to clarify the clinical characteristics of imported and second-generation cases.Methods This retrospective, multicenter cohort study included 134 confirmed COVID-19 cases from 9 cities outside Wuhan. Epidemiological, clinical and outcome data were extracted from medical records and were compared between severe and non-severe cases. We further profiled the dynamic laboratory findings of some patients.Results 34.3% of the 134 patients were severe cases, and 11.2% had complications. As of March 7, 2020, 91.8% patients were discharged and one patient (0.7%) died. The median age was 46 years. The median interval from symptom onset to hospital admission was 4.5 (IQR 3-7) days. The median lymphocyte count was 1.1×109/L. Age, lymphocyte count, CRP, ESR, DBIL, LDH, HBDH showed difference between severe and no-severe cases (all P<0.05). Baseline lymphocyte count was higher in the survived patients than in the non-survivor case, and it increased as the condition improved, but declined sharply when death occurred. The IL-6 level displayed a downtrend in survivors, but rose very high in the death case. Pulmonary fibrosis was found on later chest CT images in 51.5% of the pneumonia cases.Conclusion Imported and second-generation cases outside Wuhan had a better prognosis than initial cases in Wuhan. Lymphocyte count and IL-6 level could be used for evaluating prognosis. Pulmonary fibrosis as the sequelae of COVID-19 should be taken into account.Summary Imported and second-generation cases manifested less complications, lower fatality, and higher discharge rate than initial cases, which may be related to the shorter interval from symptom onset to hospital admission, younger age, and higher lymphocyte count of the imported and second-generation patients. Lymphocyte count and IL-6 level could be used as indicators for evaluating prognosis. Pulmonary fibrosis was found in later chest CT images in more than half of the pneumonia cases and should be taken into account.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Major Projects of Ministry of Science and Technology of the People’s Republic of China (No.2017ZX10103004-010; to Mingwei Chen); Science and Technology Planning Project of Xi 'an (No.20200003YX003(3); to Mingwei Chen).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo additional data available.